Dublin, June 18, 2025 (GLOBE NEWSWIRE) -- The "Narcolepsy: Market View" report has been added to ResearchAndMarkets.com's offering.
The Narcolepsy Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
This report provides a data-driven overview of the current and future competitive landscape in Narcolepsy Therapeutics.
Report Scope:
- The analyst epidemiologists estimate that there were 735,082 diagnosed prevalent cases of Narcolepsy in 2024, which is expected to increase slightly to 761,297 diagnosed prevalent cases by 2029.
- Currently, the narcolepsy market is saturated with generic drugs, and few innovative therapies are available in the market.
- The narcolepsy pipeline holds 28 molecules, with no assets in the pre-registration stage, five assets in Phase III development, and another four in Phase II.
- Over the past decade, 115 clinical trials have been conducted in narcolepsy.
- Over the past decade, acquisitions have been the predominant deal type for narcolepsy assets in North America.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Narcolepsy Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Narcolepsy Therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Key Topics Covered:
1 Preface
2 Key Findings
3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview
4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Molecule Type
4.4 Product Profiles and Sales Forecast
5 Pricing and Reimbursement Assessment
5.1 Annual Cost of Therapy
5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
6.1 Mid-to-late-stage Pipeline Drugs
6.2 Overview by Development Stage
6.3 Overview by Mechanism of Action
6.4 Overview by Molecule Type
6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
6.6 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
7.1 Historical Overview
7.2 Overview by Phase
7.3 Overview by Status
7.4 Overview by Phase for Ongoing and Planned Trials
7.5 Trials with Virtual Components
7.6 Overview of Trials by Geography
7.7 Single-Country and Multinational Trials by Region
7.8 Top 20 Sponsors with Breakdown by Phase
7.9 Top 20 Sponsors with Breakdown by Status
7.10 Overview by Endpoint Status
7.11 Overview by Race and Ethnicity
7.12 Enrollment Data
7.13 Top 20 countries for Trial Sites
7.14 Top 20 Sites Globally
7.15 Feasibility Analysis - Geographic Overview
7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
8.1 Mergers, Acquisitions, and Strategic Alliances by Region
8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
9.1 Key Market Players
10 Future Market Catalysts
For more information about this report visit https://www.researchandmarkets.com/r/9tcmjh
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
